Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly's phase 3 SURMOUNT-1 trial results for tirzepatide, presented at the ADA's 82nd Scientific Sessions and published in NEJM, show significant weight loss in adults with obesity. Participants lost an average of 16.0% to 22.5% of body weight over 72 weeks, with 89%-96% achieving at least 5% reduction compared to 28% on placebo. Secondary endpoints also met, reinforcing tirzepatide's efficacy. Adverse events were primarily mild to moderate gastrointestinal issues, with treatment discontinuation rates lower than placebo. Lilly anticipates further results from additional SURMOUNT trials in 2023.
Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022. Key executives, Anne White and Mark Mintun, will engage in a fireside chat at 1:40 p.m. ET. Investors can listen to the event via a live audio webcast on Lilly's Investor website, with a replay available for 90 days. Founded nearly 150 years ago, Lilly is committed to advancing health solutions that positively impact over 47 million people globally. For more information, visit Lilly.com.
Eli Lilly and Company (NYSE: LLY) has announced that data from its oncology portfolio will be showcased at the 2022 ASCO Annual Meeting from June 3-7, 2022. Key presentations include analyses from the Phase 3 monarchE study of Verzenio (abemaciclib) focusing on treatment discontinuation in high-risk HR+, HER2- early breast cancer. Updates on Retevmo (selpercatinib) will highlight its efficacy in RET fusion-positive solid tumors, while results from the Phase 1 EMBER trial on the investigational drug imlunestrant will also be presented. The event promises significant insights into cancer treatment advancements.
Bigfoot Biomedical has appointed Matt Rainville as Chief Commercial Officer, aiming to enhance the Bigfoot Unity® Diabetes Management Program. With over 20 years in healthcare commercialization, including roles at Insulet and Eli Lilly, Rainville will focus on expanding access to diabetes management solutions. CEO Jeffrey Brewer emphasized that this hiring is crucial as they seek to grow their presence in the market for insulin management. Rainville's leadership is expected to drive adoption of their innovative solutions for diabetes care.
Eli Lilly and Company (NYSE: LLY) has announced a significant expansion of its manufacturing capabilities in Indiana with a $2.1 billion investment in two new sites at the LEAP Lebanon Innovation District. This initiative aims to enhance the production of active ingredients and innovative therapies, supporting a growing pipeline of medicines. The project is expected to create 500 new jobs at Lilly and 1,500 construction positions, reinforcing Lilly's pivotal role in Indiana's economy. The expansion is contingent upon local zoning approvals.
Eli Lilly's Phase 3 LUCENT-2 study on mirikizumab shows that 50% of ulcerative colitis patients achieved clinical remission after one year, with almost all not using steroids. The drug outperformed placebo across all key endpoints, with 63.6% maintaining remission. Patients reported significant reductions in bowel urgency severity, and adverse events were lower compared to placebo. Lilly seeks regulatory approvals in the US and EU in 2023, potentially positioning mirikizumab as the first anti-IL23p19 treatment for ulcerative colitis.
Eli Lilly and Company (NYSE: LLY) is hosting a webcast on June 7, 2022, at 11:30 a.m. ET, discussing its diabetes and obesity portfolio. Key topics include results from the tirzepatide SURMOUNT-1 clinical trial and details on Lilly's weekly basal insulin and early-phase incretins. The event will be accessible via the company's Investor website, with a replay available for 90 days following the event. Lilly aims to advance healthcare solutions addressing significant health challenges, including diabetes and obesity.
Eli Lilly and Incyte announced a positive opinion from the European Medicines Agency's CHMP for OLUMIANT (baricitinib) to treat adults with severe alopecia areata. This opinion signals the potential for the first oral treatment and JAK inhibitor for severe alopecia areata in the EU, pending final approval from the European Commission, expected in the next 1-2 months. The judgment is based on the successful Phase 3 BRAVE-AA1 and BRAVE-AA2 trials, involving 1,200 patients, showing significant efficacy compared to placebo. The FDA has granted priority review for the same indication in the U.S.
Eli Lilly and Company (NYSE: LLY) will participate in the UBS Global Healthcare Conference on May 24, 2022, at 8:30 a.m. ET. Michael Mason, the Senior Vice President and President of Lilly Diabetes, will engage in a fireside chat at the event. A live audio webcast of this presentation will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly focuses on advancing healthcare solutions, impacting over 47 million people globally through innovative therapies targeting major health challenges. For more details, visit Lilly.com.
The FDA has approved Mounjaro (tirzepatide) for adults with type 2 diabetes, marking it as the first GIP and GLP-1 receptor agonist. Mounjaro is set to provide significant A1C reductions of 1.7% to 2.4% and promote weight loss, with average reductions ranging from 12 to 25 lbs. in clinical trials. It will be available in the U.S. in multiple doses. Side effects include nausea and a boxed warning for thyroid tumors. Lilly aims to enhance access through partnerships with insurers and plans to offer savings cards to eligible patients.